Centessa Pharmaceuticals plc is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process. The company applies an asset-centric R&D model at scale to advance a portfolio of highly validated programs led by industry leading teams. Each program is developed by a Centessa subsidiary and supported by a centralized infrastructure and the Centessa management team. The company is headquartered in Cambridge, Mass.
Location: United Kingdom, England, London
Employees: 51-200
Total raised: $250M
Founded date: 2021
Investors 6
| Date | Name | Website |
| 02.03.2021 | Logos Capi... | logoscapit... |
| 01.02.2022 | Vida Ventu... | vidaventur... |
| 13.07.2025 | Foresite C... | foresiteca... |
| - | Access Bio... | accessbio-... |
| - | EcoR1 Capi... | ecor1cap.c... |
| 18.05.2023 | Cambridge ... | cic.vc |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 17.02.2021 | Series A | $250M | - |
Persons 17
| Date | First Name | Last Name | Title | Location | |||
| - | Iqbal | Hussain | General Co... | linkedin.c... | - | i*********... | - |
| - | David | Chao | Chief Admi... | linkedin.c... | - | d********o... | - |
| - | Bryana | Smith, CPA | Senior Gen... | linkedin.c... | - | b*********... | - |
| - | Heike | Westphal | Executive ... | linkedin.c... | - | h*********... | - |
| - | Tia | Bush | Chief Qual... | linkedin.c... | - | t******h@c... | - |
| - | Saurabh | Saha MD Ph... | - | linkedin.c... | - | s*********... | - |
| - | Pennylynn | Makiya | - | linkedin.c... | - | p*********... | - |
| - | Shane | Lafayette | - | linkedin.c... | - | s*********... | - |
| - | Gregory | Weinhoff | Chief Fina... | linkedin.c... | - | g*********... | - |
| - | Elana | Furman | Senior Dir... | linkedin.c... | - | e*********... | - |
Show more
Mentions in press and media 27
| Date | Title | Description |
| 12.09.2024 | Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares | BOSTON and LONDON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced t... |
| 11.09.2024 | Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares | BOSTON and LONDON, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced t... |
| 13.06.2024 | The Lustgarten Foundation Appoints Two New Board Members | To date, the foundation has invested more than $282M in high-risk, high-reward research to accelerate and expand life-saving treatment options. Richard Barakat, MD, and Aaron Kantoff join the Lustgarten Foundation Board of Directors WOODBUR... |
| 13.06.2024 | Global Gene's RARE-X and Sleep Consortium Launch Sleep Data Collection Initiative to Accelerate Development of Therapies | Global Genes The Sleep Data Collection Initiative, the first consortium on the RARE-X platform for the collection and sharing of patient-owned data, brings together patient advocacy organizations, researchers, and drug developers looking to... |
| 23.04.2024 | Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares | - |
| 23.04.2024 | Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares | - |
| 14.12.2021 | Centessa Pharmaceuticals Initiates Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease, Reports Initial Positive Safety Data from ALERT Study, and Announces Notic... | ~ Initiation of registrational Phase 3 ACTION clinical study with lixivaptan is an important milestone to bring this potential new treatment option to ADPKD patients ~ ~ All four subjects in the ALERT Study who previously discontinued JYNAR... |
| 01.11.2021 | Centessa Pharmaceuticals Demonstrates Proof-of-Mechanism from First Three PiMZ Subjects Dosed in Part B of Phase 1 Study Evaluating ZF874 | ~ First demonstration that a pharmacological chaperone can provide sufficient functional Z-A1AT increases to potentially achieve greater than 11 micromolar levels in individuals with PiZZ genotype ~ ~ One subject with two-fold higher exposu... |
| 07.10.2021 | Centessa Pharmaceuticals объявляет о финансовом соглашении на 300 миллионов долларов США с Oberland Capital | БОСТОН и ЛОНДОН, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc («Центесса» или «Компания») (Nasdaq: CNTA), компания клинического уровня, использующая свою инновационную бизнес-модель, ориентированную на активы, для обнаруже... |
| 06.10.2021 | Centessa Pharmaceuticals benoemt David Grainger, PhD, een toonaangevende biotechondernemer, tot Chief Innovation Officer | BOSTON en LONDON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc ("Bedrijf") (Nasdaq: CNTA), een bedrijf in klinische fases dat zijn innovatieve assetgerichte bedrijfsmodel gebruikt om belangrijke geneesmiddelen te... |
Show more